Digitoxin and its analogs as novel cancer therapeutics

A growing body of evidence indicates that digitoxin cardiac glycoside is a promising anticancer agent when used at therapeutic concentrations. Digitoxin has a prolonged half-life and a well-established clinical profile. New scientific avenues have shown that manipulating the chemical structure of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbaz, Hosam A, Stueckle, Todd A, Tse, William, Rojanasakul, Yon, Dinu, Cerasela Zoica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506989/
https://www.ncbi.nlm.nih.gov/pubmed/23210930
http://dx.doi.org/10.1186/2162-3619-1-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506989/
https://www.ncbi.nlm.nih.gov/pubmed/23210930
http://dx.doi.org/10.1186/2162-3619-1-4

Ejemplares similares